← board
PTN
Palatin Technologies, Incdistress 9/10 · high distress / dilution risk$8.01-2%today-71% from 52w high
Immunology / Inflammation 1Metabolic / Obesity 1
Lead: rare obesity disorders (hypothalamic obesity · target GLP-1/GIP · est. market ~$15B (approx, global)
Revenue
$13M
Liquidity
$10M
Runway
0.5 yrs
Shares 1y
+83%
Price & events
-52.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.7%
1D
-5.5%
1W
-28.5%
1M
-61.0%
3M
-51.7%
6M
-40.7%
1Y
-90.5%
2Y
-98.8%
5Y
-99.1%
All
Overview
- Market Cap
- $14.25M
- Volume
- 818
- 52 Week Range
- $5.45 – $28.00
- Total Shares
- 1.78M
- Float Shares
- 1.38M
- Short %
- 10.79%
- % Held by Insiders
- 7.89%
- % Held by Institutions
- 55.58%
- RVOL
- 0.04x
- Beta
- -0.07
Pipeline stages · 2 programs
PL8177
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
bremelanotide, tirzepatideGLP-1/GIP
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-02-10 | Phase 2 | PL8177 | Ulcerative Colitis, Ulcerative Colitis Acute, Ulcerative, Ulcerative Colitis Flare | 16 | active not recruiting |
| 2025-02-05 | Phase 2 | bremelanotide, tirzepatide | Obesity | 108 | active not recruiting |
Catalyst news & presentations · 7
- first half of calendar 2027Guided 55%regulatory submissionFiled (NDA/BLA)oral MC4R selective agonist · IND submission for oral MC4R agonist programSEC 8-K
- fourth quarter of calendar 2026Guided 70%regulatory submissionFiled (NDA/BLA)once-weekly injectable MC4R selective peptide agonist · IND submission for injectable MC4R agonist programSEC 8-K
- 2025-08-18partnershipStrategic partnership with Boehringer Ingelheim for melanocortin receptor treatments in retinal diseasesSEC 8-K
- 2025-08-14partnershipmelanocortin receptor-targeted peptides · Global research collaboration and licensing agreement with Boehringer Ingelheim to develop first-in-class melanocortin receptor agonists for retinal diseases, including diabetic retinopathy. Upfront €2M, potential milestones up to €280M, tiered royalties.SEC 8-K
- 2025-08-01partnershipBusiness development collaboration with Boehringer Ingelheim in August 2025.SEC 8-K
- 2025-05-07withdrawalNYSE Regulation suspended trading and commenced delisting proceedings for Palatin's common stock.SEC 8-K
- 2025-04-10warning letterReceived delisting notice from NYSE American for failure to regain compliance with stockholders' equity requirementsSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-12-12Laidlaw & Co.Buy
- 2025-02-13HC Wainwright & Co.Buy
- 2025-02-07HC Wainwright & Co.Buy
- 2024-12-19HC Wainwright & Co.Buy
- 2024-11-25HC Wainwright & Co.Buy
- 2024-11-04HC Wainwright & Co.Buy
Competitors — GLP-1/GIP
Recent news
- 2026-07-22What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity - TipRanks
- 2026-07-21Palatin stock trades quietly as revenue stabilizes after FY 2025 loss - Ad-hoc-news.de
- 2026-07-17Palatin Technologies (PTN) CFO has 195 shares withheld for taxes - Stock Titan
- 2026-07-17Palatin Technologies (PTN) CEO has 294 shares withheld for taxes - Stock Titan
- 2026-07-15PTN Extra: Who’s heading to SEC Media Days, and Is Coach Cal’s Roster Set After the Latest Commitment? - KNWA FOX24
- 2026-07-15PTN Extra: Who's heading to SEC Media Days, and Is Coach Cal's Roster Set After the Latest Commitment? - KNWA FOX24
- 2026-07-15PTN Extra: Who's heading to SEC Media Days, and Is Coach Cal's Roster Set After the Latest Commitment? - KARK
- 2026-07-12PTN extra: What to expect from SEC media days and where will the Diamond Hogs stand after the MLB draft? - MSN
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.